Peter Hammond

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

Roel P.L.M. Hoogma, Peter Hammond, Ramón Gomis et al. · Diabetic Medicine · 2005 · 254 citations · Full text

Medicine, Endocrinology, Internal Medicine +16

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia

Pratik Choudhary, John Shin, Yongyin Wang et al. · Diabetes Care · 2011 · 175 citations · Full text

Medicine, Endocrinology, Internal Medicine +17

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

María J. Redondo, Susan Geyer, Andrea K. Steck et al. · Diabetes Care · 2018 · 169 citations · Full text

Life Sciences, Endocrinology, Genetics +17

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Emanuele Bosi, Pratik Choudhary, Harold W. de Valk et al. · The Lancet Diabetes & Endocrinology · 2019 · 123 citations

Medicine, Endocrinology, Diabetology +13